Phase II, multicenter, randomized, double-blind, placebo-controlled dose-finding study to evaluate the efficacy and safety of IMU-838 in induction and maintenance therapy in moderate to severe ulcerative colitis. CALDOSE I
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: IMMUNIC AG
- Phase: II
- Execution start: 30/05/2018
- End of execution: 22/01/2020
- IP: MARIA JOSE CABELLO TAPIA